Table 2.

Clinically relevant bleeding events in orally anticoagulated patients versus the remainder of the study cohort.

Variable n (%)	All Patients (n = 328)	No OAC (n = 116)	OAC (n = 212)	p-Value	NOAC (n = 74)	VKA (n = 138)	p-Value
Bleeding events, n (%)	54 (16.5)	5 (4.3)	49 (23.1)	<0.001	16 (21.6)	33 (23.9)	<0.001
Cerebral bleeding, n (%)	4 (1.2)	0 (0.0)	4 (1.9)	0.137	0 (0.0)	4 (2.9)	0.062
Gastrointestinal bleeding, n (%)	21 (6.4)	3 (2.6)	18 (8.5)	0.037	6 (8.1)	12 (8.7)	0.111
Urogenital bleeding, n (%)	5 (1.5)	1 (0.9)	4 (1.9)	0.469	1 (1.4)	3 (2.2)	0.690
Hematoma bleeding, n (%)	8 (2.4)	0 (0.0)	8 (3.8)	0.034	5 (6.8)	3 (2.2)	0.013
Nasal bleeding, n (%)	14 (4.3)	1 (0.9)	13 (6.1)	0.024	3 (4.1)	10 (7.2)	0.043
Other bleeding, n (%)	2 (0.6)	0 (0.0)	2 (0.9)	0.294	1 (1.4)	1 (0.7)	0.493

OAC, oral anticoagulation; NOAC, non-vitamin K oral anticoagulant; VKA, vitamin K antagonist Clinically relevant bleeding events were defined in accordance to the definition of major bleeding recommended by the International Society on Thrombosis and Haemostasis [22]. Major bleeding was defined as fatal bleeding and/or bleeding into a critical organ (intracranial, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular) and/or clinically relevant bleeding with a drop in hemoglobin ≥ 2 g/dL or requiring to transfusion. Values are given as total numbers (n) and percent (%). Bold indicates p < 0.05.